A few-year-old review that might be useful is:
Pardi, N., Hogan, M., Porter, F. et al. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov 17, 261–279 (2018). https://doi.org/10.1038/nrd.2017.243
The tricky part of creating an mRNA vaccine once the "platform" has been developed remains exactly what mRNA sequence do you put into it? ...
From the links you've supplied, none of these other vaccines have gotten further than phase 2 trials yet. Most seem to only have phase 1 trials started or merely planned so far.
These vaccines are not yet available because they have not completed clinical trials that demonstrate safety and efficacy.
Type 1 and type 2 are different viruses and once you have a herpes infection, you will always have the infection as it is lifelong (WHO, 2020).
Infection with herpes simplex virus, commonly known as herpes, can be due to either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2). HSV-1 is mainly transmitted by oral-to-oral contact to ...
This is certainly possible, however unlikely. It is also not possible to determine the probability that you would be infected.
The person have a visible infection at the time of the event. This would further reduce the probability of infection.
Symptoms can appear one to three weeks after infection.
Alternatively a blood test can detect if you are ...